nVerses Capital’s Zymeworks ZYME Stock Holding History

nVerses Capital’s Portfolio ZYME Stock Details ZYME Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-6,300	Closed	-$79.1K	–	926
2024 Q3	$79.1K	Buy	+6,300	New	+$68.6K	0.04%	525
2024 Q2	–	Sell	-3,400	Closed	-$35.8K	–	1239
2024 Q1	$35.8K	Buy	+3,400	New	+$37.8K	0.09%	325

Other funds holding ZYME

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BNP Paribas Asset Management Paris, France $86.1B AUM 29.11% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

nVerses Capital's ZYME Position: Q4 2024 in Review

nVerses Capital sold out of Zymeworks (ZYME) in Q4 2024, closing a stake of 6,300 shares — an estimated $79.1K sold.

nVerses Capital first reported a position in ZYME in Q1 2024 and held it in 2 quarters. The position peaked at $79.1K in Q3 2024. 172 funds tracked by Wall St. Rank hold ZYME as of Q4 2024.

nVerses Capital reported no remaining Zymeworks position as of Q4 2024 after selling out during the quarter.
nVerses Capital sold 6,300 Zymeworks shares in Q4 2024, an estimated $79.1K.
nVerses Capital first reported a position in Zymeworks in Q1 2024 and held it in 2 quarters.
nVerses Capital's Zymeworks position peaked at $79.1K in Q3 2024.
172 funds tracked by Wall St. Rank held Zymeworks as of Q4 2024.

Based on nVerses Capital's 13F filing for Q4 2024.